Female GH Optimization
85
协同作用
2
2,200
intermediate
May 17, 2026
概述
The Female GH Optimization stack pairs Ipamorelin with Tesamorelin specifically because these two peptides offer the most favorable side-effect profile for women seeking growth hormone benefits without androgenic or metabolic complications. Tesamorelin is a 44-amino-acid GHRH analog that is the only peptide in this category with full FDA approval (marketed as Egrifta for HIV-associated lipodystrophy). It stimulates pituitary GH production through the GHRH receptor, producing physiological GH pulses that closely mimic natural secretion patterns. Women naturally produce more GH than men (approximately 2x the daily output) but experience a sharper decline with age, making GH optimization particularly impactful for female physiology. Tesamorelin has been shown in clinical trials to reduce visceral adipose tissue by 15-20% without affecting subcutaneous fat — making it uniquely suited for the central adiposity pattern common in perimenopause and menopause. Its effects on IGF-1 are modest and predictable, staying within physiological ranges. Ipamorelin complements Tesamorelin by adding ghrelin-pathway stimulation without the appetite increase, cortisol elevation, or prolactin changes seen with other GH secretagogues. For women, the absence of prolactin effects is particularly important as elevated prolactin can disrupt menstrual cycles and breast tissue. The combination produces amplified GH pulses (via GHRH + GHS synergy) while maintaining clean hormonal profiles. Benefits typically observed include improved skin elasticity and thickness, reduced visceral fat, better sleep architecture, improved bone mineral density markers, and enhanced recovery from exercise. This stack is well-suited for women over 35 seeking comprehensive anti-aging and body composition benefits.
给药方案
200 mcg
每剂
2,000 mcg
每剂
目标与证据
警告
- Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Off-label use for anti-aging is common but not approved. Ipamorelin remains FDA Category 2 (restricted) as of July 2026.
Comments
Sign in to join the discussion
免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。